Skip to content
RL

Rekvina Labs

526075 BSE
₹56.99

Close ·

P/E
Not meaningful: loss-making over the last twelve months
View as Markdown
MCP
Close 4 Nov 2026 ₹56.99 +49.91 +705% since 13 Jan 2026
Start ₹7.08

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Standalone · TTM

ROCE
Not meaningful: the figure is far outside this ratio’s usual range, as its base is close to zero
Debt to Equity
Not meaningful: shareholders’ equity is negative
EPS (TTM)
−₹0.27
Book Value
—
Market Cap
—
P/E (TTM)
Not meaningful: loss-making over the last twelve months
P/B
Not meaningful: book value is negative
ROE
Not meaningful: shareholders’ equity is negative
Dividend Yield
0.00%
EBITDA
−₹30.00 L
52W High
₹65.07
52W Low
₹6.75

Key Insights

Strengths

1
  • Promoter holding has increased by 35.7% over last quarter.

Weaknesses

2
  • Company has low interest coverage ratio.
  • Company has high debtors of 172 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish379
OscillatorsBearish270
Moving AveragesStrong Bullish109

Key readings

RSI (14)
52.64
Neutral
MACD (12,26,9)
1.01
Bearish
SMA (50)
54.01
Bullish
SMA (200)
36.09
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+35.70%
5YZero base
3YZero base
1YZero base
TTMZero base

Net profit

Net profit growth by window
10YLoss widened by ₹0.19 Cr
5YLoss widened by ₹0.19 Cr
3YTurned to loss
1YLoss widened by ₹0.11 Cr
TTMLoss widened by ₹0.16 Cr

Operating cash flow

Operating cash flow growth by window
10YOutflow widened by ₹0.55 Cr
5YOutflow widened by ₹0.58 Cr
3YTurned negative
1YOutflow widened by ₹0.40 Cr
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+80.31 pp
5YNo sales
3YNo sales
1YNo sales
TTMNo sales

Revenue by year

Revenue by year, ₹ crore
Mar 2016₹0.06 Cr
Mar 2017₹0.00 Cr
Mar 2018₹0.00 Cr
Mar 2020₹0.00 Cr
Mar 2021₹0.00 Cr
Mar 2022−₹0.04 Cr
Mar 2023₹0.00 Cr
Mar 2024₹0.00 Cr
Mar 2025₹0.00 Cr
Mar 2026₹1.27 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2016−₹0.06 Cr
Mar 2017−₹0.02 Cr
Mar 2018−₹0.08 Cr
Mar 2020₹0.00 Cr
Mar 2021−₹0.06 Cr
Mar 2022−₹0.08 Cr
Mar 2023₹0.00 Cr
Mar 2024−₹0.02 Cr
Mar 2025−₹0.14 Cr
Mar 2026−₹0.25 Cr

Quarterly Results

₹ Cr
526075 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0
0
0
0
0
0
0
0
0
0.2
0.35
0.72
0.67
Expenses
0
0.01
0
0
0
0.07
0.02
0.04
0.04
0.23
0.47
0.78
0.79
Operating Profit
0
−0.01
0
0
0
−0.07
−0.02
−0.04
−0.04
−0.03
−0.12
−0.06
−0.12
OPM %
—
—
—
—
—
—
—
—
—
−15%
−34.29%
−8.33%
−17.91%
Other Income
0
0
0
0
0
0
0
0
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0
−0.01
0
0
0
−0.07
−0.02
−0.04
−0.04
−0.03
−0.12
−0.06
−0.12
Tax %
—
0%
—
—
—
0%
0%
0%
0%
0%
0%
0%
0%
Net Profit
0
−0.01
0
0
0
−0.07
−0.02
−0.04
−0.04
−0.03
−0.12
−0.06
−0.12
EPS (₹)
0
−0.01
0
0
0
−0.06
−0.02
−0.03
−0.03
−0.02
−0.1
−0.05
−0.1

Profit & Loss

₹ Cr
526075 profit and loss, annual, ₹ crore
Particulars Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0.08
0.03
0.06
0
0
0
0
−0.04
0
0
0
1.27
1.94
Expenses
0.05
0.03
0.12
0.05
0.1
0.15
0.06
0.04
0
0.02
0.14
1.52
2.27
Operating Profit
0.03
0
−0.06
−0.05
−0.1
−0.15
−0.06
−0.08
0
−0.02
−0.14
−0.25
−0.33
OPM %
37.5%
0%
−100%
—
—
—
—
—
—
—
—
−19.69%
−17.01%
Other Income
0
0
0
0.03
0.02
0.15
0
0
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0.03
0
−0.06
−0.02
−0.08
0
−0.06
−0.08
0
−0.02
−0.14
−0.25
−0.33
Tax %
33.33%
—
0%
0%
0%
—
0%
0%
—
0%
0%
0%
—
Net Profit
0.02
0
−0.06
−0.02
−0.08
0
−0.06
−0.08
0
−0.02
−0.14
−0.25
−0.33
EPS (₹)
0.02
0
−0.05
−0.02
−0.07
0
−0.05
−0.07
0
−0.02
−0.12
−0.21
−0.27
Div. Payout %
0%
—
0%
0%
0%
—
0%
0%
—
0%
0%
0%
—

Balance Sheet

₹ Cr
526075 balance sheet, annual, ₹ crore
Particulars Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
3.01
3.01
3.01
3.01
3.01
3.01
3.01
3.01
3.01
3.01
3.01
3.01
Reserves
−2.33
−2.45
−2.51
−2.53
−2.61
−2.86
−2.92
−3
−3
−3.21
−3.35
−4.24
Borrowings
0
0.01
0.01
0.17
0.21
0
0
0
0.08
0.04
0.25
1.47
Other Liabilities
0.09
0.09
0.13
0.14
0.19
0.13
0.15
0.18
0.11
0.17
0.12
0.94
Total Liabilities
0.77
0.66
0.64
0.79
0.8
0.28
0.24
0.19
0.2
0.01
0.03
1.18
Fixed Assets
0.27
0.15
0.15
0.15
0.15
0.15
0.15
0.15
0.15
0
0
0
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0
0
0
Other Assets
0.45
0.46
0.44
0.59
0.6
0.08
0.04
−0.01
0
0.01
0.03
1.18
Total Assets
0.77
0.66
0.64
0.79
0.8
0.28
0.24
0.19
0.2
0.01
0.03
1.18

Cash Flow

₹ Cr
526075 cash flow, annual, ₹ crore
Particulars Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−0.01
−0.02
−0.04
0.01
−0.02
−0.01
−0.01
−0.04
0.01
−0.01
−0.19
−0.59
Investing
0.01
0.02
0.07
−0.07
0
0
0
0.04
0
0
0
0
Financing
0
0.01
0
0.16
0.04
0
0
0
0
0.01
0.21
0.58
Net Cash Flow
0
0
0.03
0.1
0.01
−0.01
−0.01
0
0.01
0
0.02
−0.01
Free Cash Flow
−0.01
−0.02
−0.04
0.01
−0.02
−0.01
−0.01
−0.04
0.01
−0.01
−0.19
−0.59
CFO/OP
−33
—
67
−20
20
7
17
50
—
50
136
236

Ratios

526075 financial ratios, annual
Particulars Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
1,004
3,042
1,703
—
—
—
—
—
—
—
—
172
Inventory Days
—
—
—
—
—
—
—
—
—
—
—
0
Cash Conversion Cycle
1,004
3,042
1,703
—
—
—
—
—
—
—
—
172
Working Capital Days
1,460
4,015
1,460
—
—
—
—
—
—
—
—
−359
ROCE %
4.51%
0%
−11.11%
−3.45%
−12.7%
—
−50%
−160%
0%
—
—
−333.33%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Rekvina Labs insights

52 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 77.00%
  • Public 20.03%
  • Others 2.97%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Rekvina Labs

What does Rekvina Labs Ltd do?
Rekvina Laboratories Limited is engaged in the manufacturing and marketing of pharmaceutical formulations.
Where is Rekvina Labs Ltd (VINRKLB) listed?
Rekvina Labs Ltd trades under code 526075 on the BSE.
Which sector does Rekvina Labs Ltd belong to?
Rekvina Labs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Rekvina Labs Ltd?
Over the last 52 weeks Rekvina Labs Ltd has traded between ₹6.75 and ₹65.07 as of 4 Nov 2026.

Company Information

Rekvina Laboratories Limited is engaged in the manufacturing and marketing of pharmaceutical formulations.

Website rekvinalaboratories.com
Face Value ₹5

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/526075.md for Rekvina Labs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month